Lyka Generics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 11 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.70 Cr
- Satisfied Charges ₹ 3.68 M
- Revenue Growth 294.96%
- Profit Growth 13962.03%
- Ebitda 12467.41%
- Net Worth 8988.59%
- Total Assets 430.92%
About Lyka Generics
Lyka Generics Limited (LGL) is a leading Public Limited Indian Non-Government Company incorporated in India on 16 March 2013 and has a history of 11 years and ten months. Its registered office is in Raigarh, Maharashtra, India.
The Corporate was formerly known as Lyka Animal Healthcare Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹4.70 Cr. The company has closed loans amounting to ₹3.68 M, as per Ministry of Corporate Affairs (MCA) records.
Kunal Gandhi, Alisha Gandhi, and Narendra Rathod serve as directors at the Company.
Company Details
-
Location
Raigarh, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85100MH2013PLC241035
-
Company No.
241035
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
16 Mar 2013
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Lyka Generics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kunal Gandhi
|
Director | 16-Mar-2013 | Current |
|
Alisha Gandhi
|
Director | 01-Aug-2019 | Current |
|
Narendra Rathod
|
Director | 10-Oct-2022 | Current |
Financial Performance of Lyka Generics.
Lyka Generics Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 294.96% increase. The company also saw a substantial improvement in profitability, with a 13962.03% increase in profit. The company's net worth Soared by an impressive increase of 8988.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lyka Generics?
In 2023, Lyka Generics had a promoter holding of 99.99% and a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Lyka Labs LimitedKunal Gandhi is a mutual person
-
Lyka Bdr International Limited
Kunal Gandhi is a mutual person
-
Lyka Exports Limited
Narendra Rathod is a mutual person
-
Enai Trading And Investment Private LimitedKunal Gandhi and Narendra Rathod are mutual person
-
Hiralaxmi Business Finance Private Limited
Kunal Gandhi and Narendra Rathod are mutual person
Charges (Loans)
₹47.00 M
₹3.68 M
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 4.70 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 May 2024 | Axis Bank Limited | ₹2.45 Cr | Open |
| 03 Mar 2023 | Axis Bank Limited | ₹2.25 Cr | Open |
| 28 Jan 2020 | Others | ₹3.68 M | Satisfied |
How Many Employees Work at Lyka Generics?
Unlock and access historical data on people associated with Lyka Generics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lyka Generics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lyka Generics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
